treprostinil sodium

DRUG6 trials

Conditions

Hypertension, PulmonaryLiver TransplantNon-operable Chronic Thromboembolic Pulmonary HypertensionPulmonary Arterial HypertensionPulmonary Hypertension

Phase 2

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

WithdrawnNCT01884038

United TherapeuticsLiver Transplant

Start: 2008-06-30End: 2010-06-30Updated: 2023-12-19

Phase 3

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)

CompletedNCT01416636

SciPharm SàRLNon-operable Chronic Thromboembolic Pulmonary Hypertension

Start: 2009-03-31End: 2021-04-30Updated: 2022-06-07

Phase 4

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

CompletedNCT00058929

United TherapeuticsPulmonary Arterial Hypertension, Pulmonary Hypertension

Start: 2002-10-31End: 2005-08-31Target: 39Updated: 2013-03-07

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

CompletedNCT00373360

United TherapeuticsPulmonary Hypertension

Start: 2006-09-30End: 2008-01-31Updated: 2013-01-07

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

TerminatedNCT00458042

United TherapeuticsHypertension, Pulmonary

Start: 2007-03-31End: 2007-11-30Target: 10Updated: 2007-11-12

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

TerminatedNCT00643604

United TherapeuticsHypertension, Pulmonary

Start: 2008-03-31End: 2012-02-29Updated: 2024-01-03

Related Papers

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil

Pulmonary Circulation2023-07-012 citations

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.